Brand
Boehringer Ingelheim Pharmaceuticals, Inc.
1 federal recall on file. We monitor every CPSC, FDA, USDA, and NHTSA notice for Boehringer Ingelheim Pharmaceuticals, Inc. and translate it into plain English — free weekly digest, optional same-day alerts.
- 2023-03-29FDA-DrugClass IIJARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA
Labeling: Label Mix-up
Get notified about new Boehringer Ingelheim Pharmaceuticals, Inc. recalls
Free weekly digest. We email when a new federal recall affects Boehringer Ingelheim Pharmaceuticals, Inc. or anything else in your household.
Get the Sunday BriefExplore other recall topics
By hazard
By state